<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Algorithm for managing acquired/toxic methemoglobinemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Algorithm for managing acquired/toxic methemoglobinemia</h1>
<div class="graphic"><div class="figure"><div class="ttl">Algorithm for managing acquired/toxic methemoglobinemia</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">All individuals should be evaluated for other possible causes of their symptoms and other possible toxic exposures. Individuals with congenital methemoglobinemia as well as <em>CYB5R3</em> heterozygotes are likely to have increased susceptibility to acquired/toxic methemoglobinemia. For individuals with severe methemoglobinemia who require treatment, MB is preferred (when not contraindicated) due to its rapid and complete reversal of methemoglobinemia. MB can cause severe hemolysis in individuals with G6PD deficiency or life-threatening serotonin syndrome in individuals taking an SSRI or other serotonergic agent; ascorbic acid is used in these cases. Refer to UpToDate for additional details of our approach to management.</div><div class="graphic_footnotes">G6PD: glucose-6-phosphate dehydrogenase; MB: methylene blue; <em>CYB5R3</em>: cytochrome b5 reductase gene; SSRI: selective serotonin reuptake inhibitor.<br/>* Symptoms attributable to methemoglobinemia may be nonspecific (headache, lethargy, irritability); with higher levels, cyanosis, respiratory failure, neurologic changes (seizures, coma) may occur.<br/>¶ Ascorbic acid dose: 1.5 to 2 grams intravenously. Some individuals for whom G6PD status is unknown may be treated cautiously with MB instead.<br/>Δ Methylene blue dose: 1 to 2 mg/kg intravenously.<br/><font class="lozenge">◊</font> Improvement is assessed clinically; the tempo of monitoring depends on the severity of disease. Routine laboratory monitoring is not used because MB interferes with methemoglobin measurements.</div><div id="graphicVersion">Graphic 127918 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
